<IPO>HENGRUI PHARMA Clears HK Listing Hearing, Rumored to Pool Min. US$2B

2025/05/06 01:30 GMT

Recommend

Positive

Negative

SHORT SELL

STOCK INFO

A-share HENGRUI PHARMA (600276.SH) +0.160 (+0.298%) passed the hearing for listing in Hong Kong, with Morgan Stanley, Citi and Huatai International as co-sponsors.

The company would raise at least US$2 billion in Hong Kong IPO, according to earlier market hearsay.

Related NewsBOCI Expects Southbound Capital Net Inflow into HK Stocks to Reach RMB1.2T This Yr, Calls for Attention to Actively Traded Stocks Like BABA-W/ Others
Based on the company's announcement at the end of April, it had received a notification from the China Securities Regulatory Commission (CSRC) of its filing to issue no more than 815 million H shares.
(A Shares quote is delayed for at least 15 mins.)

AAStocks Financial News

Hottest Topics (last 2 hours)

254

<Research>BOCOMI: Positive Improvement Expected in Int'l/ Domestic Mkts w/ Positive Catalyst for HK Stocks; Focus on 3 Main Lines Suggested

209

<Review>MIDEA, ZTO To Become New Blue Chips; HSTECH To Add BYD, Oust CHINA LIT

208

<Research>CICC Lists Capital Flow Forecasts for Stocks w/ Major Weighting Changes After MSCI Quarterly Review (Table)

Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.